BUKO Pharma-Kampagne and the Institute of Public Health Bangalore/ India have made a survey of the business behavior of Bayer Health Care, Boehringer Ingelheim and Baxter in India. The results: these companies sell many irrational preparations and offer only few essential innovations. Bayer and Boehringer Ingelheim conduct numerous clinical trials in India, but they prefer to search for new applications of their blockbusters instead of doing research in the field of neglected diseases. Boehringer Ingelheim has a particularly poor pharmaceutical portfolio with 70% of irrational drugs and no essential preparation. Other topics of the survey focus on patent policies and marketing practices.
Download Brochure [PDF/ 1,5MB]
Update 26.9.2012: Boehringer reacts